Jacobs John C 4/A

What Happened

• John C. Jacobs, President, CEO and Director of Novavax (NVAX), received a derivative award covering 551,500 shares on March 2, 2026. The grant is reported on an amended Form 4 filed March 9, 2026. The filing shows a reported per-share price of $0.00 for the award in this amendment; the amendment was submitted to correct the exercise price and derivative price originally reported in the March 3, 2026 filing.

Key Details

• Transaction date: March 2, 2026; Form 4/A filed: March 9, 2026 (original Form 4 filed March 3, 2026).
• Transaction type: Grant / award of a derivative security (551,500 shares) reported at $0.00 per share in this amendment.
• Vesting: 1/4 of the shares vest on the first anniversary of March 2, 2026; the remaining 3/4 vest in equal monthly installments over the following three years, contingent on continued employment (see footnote F2).
• Amendment note: Filings amended to correct the exercise price and price of the derivative security from the March 3 filing; all other information unchanged (footnote F1).
• Shares owned after transaction: Not specified in this Form 4/A.

Context

• This is a granted award/derivative (not an open-market purchase or immediate sale). The award vests over four years and is tied to continued employment, so it does not represent an immediate transfer of marketable shares. The amendment to correct pricing details can affect how the award’s potential value is interpreted, but the filing itself does not indicate any immediate sale or cashless exercise.